Announcements Trials
Browse Landscape

Status

Approved for marketing 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 270Observational 59Expanded_access 1

Sponsor

Cancer Type

Thoracic 1Head & Neck 1Gastrointestinal 1Endocrine 1Breast 1

Conditions

Carcinoma, Non-Small-Cell Lung 32Multiple Myeloma 26Neoplasms 25Recurrence 23Melanoma 19Leukemia, Myeloid, Acute 16Breast Neoplasms 15Prostatic Neoplasms 12Pancreatic Neoplasms 11Glioblastoma 11Sarcoma 10Precursor Cell Lymphoblastic Leukemia-Lymphoma 9Lung Neoplasms 9Ovarian Neoplasms 8Lymphoma 8Glioma 8Colorectal Neoplasms 8Small Cell Lung Carcinoma 7Lymphoma, Large B-Cell, Diffuse 7Carcinoma, Renal Cell 7Lymphoma, Non-Hodgkin 6Leukemia, Myelogenous, Chronic, BCR-ABL Positive 6Gastrointestinal Stromal Tumors 6Cholangiocarcinoma 6Triple Negative Breast Neoplasms 5Stomach Neoplasms 5Neoplasm Metastasis 5Leukemia, Lymphocytic, Chronic, B-Cell 5Thyroid Neoplasms 4Lymphoma, Mantle-Cell 4

Interventions

selpercatinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Expanded_access × Colonic Neoplasms × Clear all
NCT03906331 2025-01-17

Expanded Access for the Treatment of Cancers With Rearranged During Transfection (RET) Activation

Eli Lilly and Company

Approved for marketing
BreastEndocrineGastrointestinalHead & NeckThoracic

Thyroid Cancer, Papillary, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Colonic Neoplasms, Pancreatic Neoplasms, Carcinoma, Medullary

Data powered by HemOnc (CC BY 4.0) Colophon âš¡